Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)-MedSci.cn

Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05)

Geyer, CE; Untch, M; Prat, A; Rastogi, P; Niikura, N; Mathias, E; McLean, LA; Wang, YB; Loibl, S

CANCER RESEARCH, 2021; 81 (4):

科室
- - 订阅+
  - 更多科室
工具
服务